# Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

> **NCT06570772** · PHASE3 · TERMINATED · sponsor: **Alvotech Swiss AG** · enrollment: 301 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** AVT16
- **BIOLOGICAL:** Vedolizumab

## Key facts

- **NCT ID:** NCT06570772
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-23
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 301 (ACTUAL)
- **Why stopped:** The study has been terminated based on Sponsor decision. This decision is not related to any safety concerns associated with the investigational products. It is related to the fact that study will be not required for product dossier submission.
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06570772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06570772, "Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06570772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*